Silence Therapeutics Net Income From Continuing Ops Over Time
| SLN Stock | USD 4.75 0.23 5.09% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Silence Therapeutics Performance and Silence Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Silence Therapeutics PLC and related stocks such as Contineum Therapeutics, Amarin PLC, and Kyverna Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTNM | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (24.3 M) | 22.7 M | (42.3 M) | (48.6 M) | (46.2 M) |
| AMRN | (166.2 M) | (166.2 M) | (166.2 M) | (166.2 M) | (56.4 M) | (115.2 M) | (86.3 M) | (67.9 M) | (116.4 M) | (22.6 M) | (18 M) | 7.7 M | (105.8 M) | (52.5 M) | (82.2 M) | (94.5 M) | (99.2 M) |
| KYTX | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (28.9 M) | (60.4 M) | (127.5 M) | (114.7 M) | (109 M) |
| ALDX | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (57.8 M) | (62 M) | (45.7 M) | (55.9 M) | (50.3 M) | (52.8 M) |
| CAPR | (4.9 M) | (4.9 M) | (1.9 M) | (8.9 M) | (6.2 M) | (12.9 M) | (18.8 M) | 2.4 M | (15.2 M) | (7.6 M) | (13.7 M) | (20 M) | (29 M) | (29.2 M) | (40.5 M) | (36.4 M) | (34.6 M) |
| LXEO | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (50.6 M) | (59.3 M) | (66.4 M) | (98.3 M) | (88.5 M) | (92.9 M) |
| LYEL | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (204.5 M) | (250.2 M) | (183.1 M) | (234.6 M) | (343 M) | (308.7 M) | (324.1 M) |
| MREO | (480 M) | (480 M) | (480 M) | (480 M) | (480 M) | (480 M) | (28.4 M) | (38.8 M) | (32 M) | (34.8 M) | (163.6 M) | 12.7 M | (34.2 M) | (29.5 M) | (43.3 M) | (49.7 M) | (52.2 M) |
| ANRO | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (27.7 M) | (36.3 M) | (61.4 M) | (61.4 M) | (55.3 M) | (52.5 M) |
| ACIU | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | 10.8 M | 20.1 M | (7.1 M) | (26.4 M) | (51 M) | 45.4 M | (61.9 M) | (73 M) | (70.8 M) | (54.2 M) | (50.9 M) | (45.8 M) | (43.5 M) |
Silence Therapeutics PLC and related stocks such as Contineum Therapeutics, Amarin PLC, and Kyverna Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Silence Therapeutics PLC | SLN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 72 Hammersmith Road, |
| Exchange | NASDAQ Exchange |
USD 4.75
Check out Silence Therapeutics Performance and Silence Therapeutics Correlation. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Silence Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.